Daniel Wierda

1.2k total citations
23 papers, 863 citations indexed

About

Daniel Wierda is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Wierda has authored 23 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 8 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Wierda's work include Immunotoxicology and immune responses (7 papers), Carcinogens and Genotoxicity Assessment (5 papers) and Animal testing and alternatives (4 papers). Daniel Wierda is often cited by papers focused on Immunotoxicology and immune responses (7 papers), Carcinogens and Genotoxicity Assessment (5 papers) and Animal testing and alternatives (4 papers). Daniel Wierda collaborates with scholars based in United States, Canada and Germany. Daniel Wierda's co-authors include Steven J. Swanson, Anthony R. Mire‐Sluis, Yu Chen Barrett, Eugen Koren, Gopi Shankar, Linda A. Zuckerman, Mauricio Maia, Viswanath Devanarayan, G. H. Scott and Elizabeth W. Shores and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Biochemical Pharmacology and Toxicology and Applied Pharmacology.

In The Last Decade

Daniel Wierda

23 papers receiving 805 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Wierda United States 12 470 321 296 112 96 23 863
Anne M. Pilaro United States 17 359 0.8× 111 0.3× 242 0.8× 302 2.7× 82 0.9× 26 1.1k
Winston Evering United States 14 309 0.7× 78 0.2× 174 0.6× 277 2.5× 55 0.6× 21 693
Kenjiro Yokoro Japan 15 161 0.3× 126 0.4× 310 1.0× 170 1.5× 118 1.2× 56 797
Yoko Hirabayashi Japan 15 229 0.5× 118 0.4× 331 1.1× 134 1.2× 209 2.2× 57 942
Teruaki Kimura Japan 16 375 0.8× 160 0.5× 321 1.1× 98 0.9× 41 0.4× 27 974
Helen G. Haggerty United States 11 183 0.4× 68 0.2× 89 0.3× 60 0.5× 28 0.3× 25 436
Toshifumi Ito Japan 18 159 0.3× 94 0.3× 653 2.2× 280 2.5× 95 1.0× 44 1.2k
D. Chimenti Italy 16 243 0.5× 165 0.5× 230 0.8× 71 0.6× 39 0.4× 24 816
R. A. Miller United States 9 138 0.3× 357 1.1× 241 0.8× 147 1.3× 397 4.1× 13 995
E. Rogier France 14 195 0.4× 94 0.3× 250 0.8× 112 1.0× 87 0.9× 23 774

Countries citing papers authored by Daniel Wierda

Since Specialization
Citations

This map shows the geographic impact of Daniel Wierda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Wierda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Wierda more than expected).

Fields of papers citing papers by Daniel Wierda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Wierda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Wierda. The network helps show where Daniel Wierda may publish in the future.

Co-authorship network of co-authors of Daniel Wierda

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Wierda. A scholar is included among the top collaborators of Daniel Wierda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Wierda. Daniel Wierda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Collinge, Mark, Leigh Ann Burns‐Naas, Gary J. Chellman, et al.. (2012). Developmental immunotoxicity (DIT) testing of pharmaceuticals: Current practices, state of the science, knowledge gaps, and recommendations. Journal of Immunotoxicology. 9(2). 210–230. 19 indexed citations
3.
Piccotti, Joseph R., Hervé Lebrec, Ellen W. Evans, et al.. (2009). Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs. Journal of Immunotoxicology. 6(1). 1–10. 6 indexed citations
4.
Smith, Holly W. & Daniel Wierda. (2005). Preclinical Immunogenicity Testing for Recombinant Therapeutic Proteins. Journal of Immunotoxicology. 2(4). 203–210. 3 indexed citations
5.
Mire‐Sluis, Anthony R., Yu Chen Barrett, Viswanath Devanarayan, et al.. (2004). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of Immunological Methods. 289(1-2). 1–16. 463 indexed citations
6.
Adkinson, N. Franklin, David M. Essayan, Rebecca S. Gruchalla, et al.. (2002). Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. Journal of Allergy and Clinical Immunology. 109(3). S461–S478. 63 indexed citations
7.
Wierda, Daniel, Holly W. Smith, & Craig Zwickl. (2001). Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology. 158(1-2). 71–74. 35 indexed citations
8.
9.
Fan, Fang, Daniel Wierda, & Karl K. Rozman. (1996). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on humoral and cell-mediated immunity in Sprague-Dawley rats. Toxicology. 106(1-3). 221–228. 40 indexed citations
10.
Updyke, Lawrence W., et al.. (1993). Age-related changes in production of interleukin-7 (IL-7) by murine long-term bone marrow cultures (LTBMC). Mechanisms of Ageing and Development. 69(1-2). 109–117. 19 indexed citations
11.
Luster, Michael I., Daniel Wierda, & Gary J. Rosenthal. (1990). Environmentally Related Disorders of the Hematologic and Immune Systems. Medical Clinics of North America. 74(2). 425–440. 7 indexed citations
12.
Reasor, Mark J., et al.. (1989). Macrophage regulation of myelopoiesis is altered by exposure to the benzene metabolite hydroquinone. Toxicology and Applied Pharmacology. 97(3). 440–453. 46 indexed citations
13.
Wierda, Daniel, Andrew King, Robert W. Luebke, Mark J. Reasor, & Ralph J. Smialowicz. (1989). Perinatal Immunotoxicity of Benzene Toward Mouse B Cell Development. Journal of the American College of Toxicology. 8(5). 981–996. 2 indexed citations
14.
Wierda, Daniel, et al.. (1988). Chlorphentermine Suppresses the Phosphatidylinositol Pathway in Concanavalin A-Activated Mouse Splenic Lymphocytes. Immunopharmacology and Immunotoxicology. 10(1). 1–19. 15 indexed citations
15.
Wierda, Daniel, et al.. (1986). Chlorphetermine-induced alterations in the response of human lymphocytes to mitogens. Biochemical Pharmacology. 35(20). 3651–3654. 2 indexed citations
16.
Dyke, Knox Van, et al.. (1985). Studies of luminol-dependent whole-blood chemiluminescence induced by platelet-activating factor (PAF). Microchemical Journal. 31(3). 261–271. 2 indexed citations
17.
18.
Irons, Richard D., William F. Greenlee, Daniel Wierda, & James S. Bus. (1982). Relationship between Benzene Metabolism and Toxicity: A Proposed Mechanism for the Formation of Reactive Intermediates from Polyphenol Metabolites. Advances in experimental medicine and biology. 136 Pt A. 229–243. 33 indexed citations
19.
Wierda, Daniel & Richard D. Irons. (1982). Hydroquinone and catechol reduce the frequency of progenitor B lymphocytes in mouse spleen and bone marrow. Immunopharmacology. 4(1). 41–54. 47 indexed citations
20.
Wierda, Daniel & Thomas L. Pazdernik. (1981). Uridine transport in concanavalin A- and lipopolysaccharide-activated mouse lymphocytes. Biochemical Pharmacology. 30(24). 3295–3303. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne M. Pilaro Breakdown of academic impact, for papers by Winston Evering Breakdown of academic impact, for papers by Kenjiro Yokoro Breakdown of academic impact, for papers by Yoko Hirabayashi Breakdown of academic impact, for papers by Teruaki Kimura Breakdown of academic impact, for papers by Helen G. Haggerty Breakdown of academic impact, for papers by Toshifumi Ito Breakdown of academic impact, for papers by D. Chimenti Breakdown of academic impact, for papers by R. A. Miller Breakdown of academic impact, for papers by E. Rogier
Rankless by CCL
2026